Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
This Review deals with recent progress in the immunotherapy of established (pre)malignant disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell responses. The most attractive vaccine compounds are synthetic long peptides (SLP) corresponding to the sequence of tumour viral antigens or tumour-associated non-viral antigens. Crucial to induction of therapeutic T-cell immunity is the capacity of SLP to deliver specific cargo to professional antigen-presenting cells (dendritic cells (DC)). Proper DC activation then induces the therapeutic CD4+ and CD8+ T-cell responses that are associated with regression of established (pre)malignant lesions, including those induced by high-risk human papilloma virus.
Melief
Cornelis J M
CJ
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. cmelief@lumc.nl
van der Burg
Sjoerd H
SH
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active; D051379:Mice; D010455:Peptides / Q000276:immunology*; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000209:etiology / Q000821:virology; D011817:Rabbits; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use
D019496:Cancer Vaccines; D010455:Peptides; D022223:Vaccines, Subunit